Dab2, first identified as a tumor suppressor in ovarian cancerous cells and tissues, is an adaptor protein involved in several signal transduction pathways. Our previous studies of mouse embryos have shown that Dab2 is expressed in the early developing central nervous system and that knockdown of the protein expression perturbs the normal development of the neural tube. In this study, we investigated Dab2 expression in the human fetal hippocampus and temporal, sensory, visual, motor and frontal cortices from 12 to 32 weeks of gestation with a specific immunohistochemical staining method. The hippocampus showed the strongest Dab2 expression among all the brain regions examined. Within the hippocampus, Dab2 expression was first detected at 12–14 weeks in all cellular layers with varying intensities, and the highest level of expression was observed in the pyramidal layer at 26–28 weeks. In the temporal cortex, Dab2 was also expressed in all cellular layers at 12–14 weeks, and its expression peaked at 18–20 weeks and then became weaker at 26–32 weeks. The expression pattern was different in the sensory cortex: the expression was the strongest at 12–14 weeks and then gradually reduced with age. In the visual cortex, Dab2 expression was mainly localized in the marginal zone, upper cortical plate and subcortical layers, whereas the motor and frontal cortices exhibited only low levels of Dab2 expression mostly in the subcortical layers. Our results demonstrated a specific spatiotemporal pattern of Dab2 expression in the human fetal hippocampus and neocortex, implicating roles of Dab2 in the early development of the human brain.

Keywords:
Dab2, Doc-2, p96, Hippocampus, Neocortex, Human fetal brain, Immunohistochemical staining, Spatiotemporal changes
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.